13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neurotechnology Developers
Neurotechnology developers work at the intersection of neuroscience and engineering, creating innovative tools that enhance our understanding of the brain and improve treatments for neurological conditions. They design and implement technologies such as brain-computer interfaces (BCIs), neural prosthetics, and neuroimaging devices to monitor, diagnose, and treat neurological disorders. These specialists collaborate with neuroscientists, clinicians, and biomedical engineers to develop devices that can interface directly with the brain, providing patients with the ability to control prosthetic limbs or communicate through thought. Neurotechnology developers are also involved in the creation of advanced neuroimaging systems, which allow for detailed, real-time observation of brain activity in patients with conditions like epilepsy or Parkinson’s disease. Their work extends to innovations in neural stimulation therapies, such as transcranial magnetic stimulation (TMS), which is used to treat mood disorders, pain, and neurological rehabilitation. With rapid advancements in artificial intelligence and machine learning, neurotechnology developers are increasingly leveraging these technologies to improve diagnostics, optimize treatment protocols, and provide personalized care. They play a pivotal role in advancing the field of neuroengineering, with the goal of improving the quality of life for individuals with neurological disorders through cutting-edge technologies.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States